Cisatracurium Besylate Injection
NDC Package 0781-3152-95

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Cisatracurium Besylate injection is an intermediate-onset/intermediate-duration neuromuscular blocking agent indicated for inpatients and outpatients as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation in the ICU. This formulation utilizes a injection delivery system. Marketed by Sandoz Inc, this product is identified by NDC 0781-3152 and is authorized under FDA application ANDA200159.

Identification & Billing

NDC Package Code
0781-3152-95
Package Description
10 VIAL, MULTI-DOSE in 1 CARTON / 10 mL in 1 VIAL, MULTI-DOSE (0781-3152-70)
Product Code
0781-3152
11-Digit Billing Format
00781315295
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk
  • RxCUI: 199211 - cisatracurium 2 MG/ML Injectable Solution
  • RxCUI: 199211 - cisatracurium (as cisatracurium besylate) 2 MG/ML Injectable Solution

Clinical Specifications

Proprietary Name
Cisatracurium Besylate
Non-Proprietary Name
Cisatracurium Besylate
Substance Name
Cisatracurium Besylate
Dosage Form
Injection - A sterile preparation intended for parenteral use; five distinct classes of injections exist as defined by the USP.
Administration Route
Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
CISATRACURIUM BESYLATE 2 mg/mL
Pharmacologic Class
Usage Information
Cisatracurium besylate injection is an intermediate-onset/intermediate-duration neuromuscular blocking agent indicated for inpatients and outpatients as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation in the ICU.

Regulatory & Marketing

Labeler Name
Sandoz Inc
Product Type
Human Prescription Drug
FDA Application #
ANDA200159
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
07-16-2012
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0781-3152-95 identifies a specific commercial package of 10 vial, multi-dose in 1 carton / 10 ml in 1 vial, multi-dose (0781-3152-70) of Cisatracurium Besylate, a human prescription drug labeled by Sandoz Inc. This injection is formulated for intravenous use and contains cisatracurium besylate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Sandoz Inc on July 16, 2012. The current certification is valid through December 31, 2026.

How is this Sandoz Inc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00781315295. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0781-3152-95
11-Digit CMS (5-4-2)
00781-3152-95

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.